Microcore NESC®  is Clinically validated for Osteoporosis & Osteopenia vide CTRI/2023/02/049901

Contains Elemental Egg Calcium 500 mg+ Cholecalciferol  600 IU+ (Equivalent  elemental magnesium 5%) Magnesium Gluconate + (Equivalent Elemental Zinc 31% ) Zinc Citrate.
 

 

Microcore NESC® is approved vide File. No:- 60/Std/PA/FSSAI/2022  Health Claim : to avoid the risk of Osteoporosis!

Patented technologies of Microcore helps to produce strontium embedded Egg Calcium with molecular interlocking based formulations that helps for sustainable release.

 

We Provide blends & finished Tablet of Microcore NESC® to improve Osteopenia and Osteoporosis! That You Can Trust!

This novel combination of ingredients of NESC, has shown a better oral relative bio availability of calcium, better improvement of BMD over a treatment period of 12 weeks.

VAS pain score Microcore NESC®

It has shown to cause a reduction in the production of pro-inflammatory cytokines, such as interleukin-1beta and tumor necrosis factor-alpha Our study has also confirmed the same by showing a reduction in VAS pain scores and improvement in performance related quality of life questionnaires.

LEARN MORE

Microcore NESC® BMD & oral relative bio availability

It has shown a better oral relative bio availability of calcium, better improvement of BMD while compared to Shelcal and CCM.
There is a significant improvement in the BMD post treatment compared to Shelcal.

LEARN MORE

 Microcore NESC® Osteocalcin

This study has also highlighted that the treatment has shown to bring down osteocalcin levels, which is marker for reduction in osteoporosis. Thus, NESC can be considered a better and safe calcium supplement.

LEARN MORE

We Are Always Ready to Help to improve   Osteopenia & Osteoporosis Conditions

Osteoporosis is a skeletal disorder characterized by a decrease in bone mass, compromised bone strength, and an increase in bone fragility predisposing to fracture. It is an important health problem in western and developing countries; in the United States alone, it is estimated that 10 million people have osteoporosis, whereas 18 million people have low bone density (having osteopenia) placing them at risk of this disorder. Osteopenia is characterized by bone loss that is not as severe as osteoporosis. Osteopenia participants land up in osteoporosis sooner or later. If we are able to identify and treat osteopenia at an early stage, we can prevent the complications that occur due to osteoporosis.

#

Microcore NESC ®  is made by innovative technologies by  Microcore Research Laboratories India Pvt Ltd https://microcoreresearch.com/  https://jointcore.us/  The technologies are  based on enhancing the porosity of micro granular Egg Shells and nano  binding  methods develped by Microcore and  both the ingredient and the brands are approved by FSSAI/STD/DELHI. The clinical studies of the  Microcore NESC®   supports the  delivery of high pure calcium carbonate with strontium made from egg shells and that contains Zinc, Magnesium, Iron and phosphorus   excellent relative bioavailability and relative absorptions  and it has  additional benefits  on bone metabolism over purified calcium perhaps and remains the most appropriate combinations to help on  STRENGTHENING  BONE MINERAL DENSITY IN OSTEOPOROSIS  & OSTEOPENIA PATIENTS. Bone mass was assessed by speed of sound (SOS) (m/s). The T-score was calculated by using the SOS value, our study indicated that the  T-scores of the eggshell calcium group were significantly higher than those of the calcium carbonate group.

CLINICAL VALIDATION

CTRI /2023/02/049901 [Registered on: 20/02/2023]

FSSAI/PA/APPROVAL

File. No:- 60/Std/PA/FSSAI/2022  Health Claim : to avoid the risk of Osteoporosis!

JOURNAL PUBLICATIONS

Under progress

248

Specialist Hospital

550

Specialist Doctors

2,34,379

Happy Patients

20

Years of Experience

 

STUDY PLAN 

TITLE

 A randomized, open label, parallel group clinical study comparing the relative bioavailability, safety and efficacy of Microcore NESC® with Calcium carbonate and Calcium citrate malate in osteopenic and osteoporotic patients.


STUDY OBJECTIVES


1. To study the efficacy and relative bioavailability of
Microcore NESC® (Natural Egg Shell Calcium) in osteopenic and osteoporotic patients.
2. To assess the safety and tolerability of
Microcore NESC®  (Natural Egg Shell Calcium) by monitoring the occurrence of any adverse effects by clinical and laboratory evaluation.

 

                                                                                                                                   PARAMETERS MONITORED

1. Bone Mineral Density (BMD)-at Baseline and at 12 weeks
2. Serum calcium test for relative absorption and bioavailability.
3. Serum osteocalcin - Baseline and at 12 weeks
4. X-ray at baseline and 12 weeks to understand any fine fracture or cracks in the osteoporotic patient and its healing or regeneration after the course of medication
5. Change from baseline to 12 weeks in knee / body pain intensity measured by pain VAS Scale (0-100mm)
6. Changes from baseline to 12 weeks in quality of life-Questionnaires (Short Form Health-36).

  •                                                                                                                                             METHODOLOGY

                                                                                                        60Participants were randomized into 3 groups with 20 in each group.

    Arm 1- Participants with osteopenia and osteoporosis took two Tablet daily of Microcore NESC
    ®  orally in the morning and night for 12 weeks
    Arm 2- Participants with osteopenia and osteoporosis took two Tablet daily of Shelcal orally in the morning and night for 12 weeks
    Arm 3- Participants with osteopenia and osteoporosis took two Tablet daily of CCM orally in the morning and night for 12 weeks.

 

REFERENCE COMPOSITIONS
 

Shelcal Tablet- Reference 1
 Calcium carbonate from organic source powdered oysters shell 1250 mg equivalent of the elemental calcium - 500 mg
 Vitamin D3 IP- 250 IU

CCM Tablet - Reference 2
 Calcium citrate malate eq. to elemental calcium 250mg
 Cholecalciferol-100IU Folic acid - 50mcg

TEST COMPOSITION

Microcore NESC®  Tablet
Calcium carbonate natural source (Natural Elemental Egg Calcium) 500 mg
Cholecalciferol ID- 600 IU Magnesium gluconate 100mg (Elemental magnesium at16% which is 16 mg)
Zinc citrate 42 mg (Elemental zinc at 31% which is 13.2 mg)

 


 

#

 

Do you need Microcore NESC? Call+919659003519

Unit-1 Registered Office| R&D | QA | Production | Microcore Research Labs India Pvt Ltd 9th km, 204-A Palani Main Road, Checkumedu, Erode - 638115 (Dt) Tamil Nadu, India. info@microcoreresearch.com +91 9659003519.

Significances of Ingredients

#

 Microcore NESC® Tablet consist of calcium carbonate natural source (Natural elemental Egg Shell Calcium) 500 mg, cholecalciferol ID- 600 IU, magnesium gluconate 100mg (Elemental magnesium at 16% which is 16 mg) and zinc citrate 42 mg (Elemental zinc at 31% which is 13.2 mg).

 

RESULTS AND DISCUSSIONS

#

This novel combination of ingredients of Microcore NESC®, has shown a better oral relative bio availability of calcium, better improvement of BMD over a treatment period of 12 weeks, while compared to other preparations like Shelcal and CCM. However, Microcore NESC® and Shelcal is showing a comparable performance in many other parameters, the bioavailability and side effect profile is better with Microcore NESC®. This study has also highlighted that Microcore NESC® treatment has shown to bring down osteocalcin levels, which is marker for reduction in osteoporosis. Thus, Microcore NESC® has natural Strontium in it. Strontium has a dual effect of inhibiting bone resorption (Osteoclastic ) and stimulating new bone formation (Osteoblastic) and its biological behavior as well as the metabolism and distribution of strontium mimics that of calcium. Studies have shown that Strontium Supplements increases bone mass density and reduces the risk of vertebral and normal bone fracture.

DEMOGRAPHIC DETAILS

Gender

Group

Total

CCM

NESC

Shelcal

Female

13

11

12

36

68.40%

61.10%

70.60%

66.70%

Male

6

7

5

18

31.60%

38.90%

29.40%

33.30%

Total

19

18

17

54

This novel combination of ingredients has shown a better oral relative bio availability of calcium, better improvement of BMD while compared to other preparations like Shelcal and CCM. There is a significant improvement in the BMD(T score) post treatment with NESC and Shelcal. Microcore NESC® is showing a higher significance when compared to Shelcal. The progression from osteopenia to Osteoporosis has been reduced, as serum carboxylated osteocalcin levels decreased from base line to post study values, in Microcore NESC® treatment group. However, there is no statistically significant reduction in any of the treatment groups. There is a higher percentage of improvement in calcium absorption as depicted by an increase in serum calcium levels (10.23%) in the Microcore NESC® treated group when compared to Shelcal (7.7%) and CCM (7.2%) at 270 minutes after administration.The relative bio availability of Microcore NESC® with respect to shelcal was 93%. For calcium, which is an endogenous substance, measurement of absolute bioavailability of an oral dose requires the use of isotopic methods, but for assessing relative oral bioavailability, the pharmacokinetic method is a convenient and acceptable tool. Hence, the same was applied here. This study has also highlighted that NESC treatment has shown to bring down osteocalcin levels, which is marker for reduction in osteoporosis. Thus, NESC can be considered a better and safe calcium supplement, as there are very few side effects observed without any clinically significant abnormalities in lab parameters and Patient compliance to the test product was exceptionally good, through out the study.

 

Medical Journal Publication data is available on genuine request

."COMPARATIVE EVALUATION OF BIOAVAILABILITY, EFFICACY AND SAFETY OF MICROCORE NESC® WITH CALCIUM CARBONATE AND CALCIUM CITRATE MALATE IN OSTEOPENIC AND OSTEOPOROTIC PATIENTS - A RANDOMIZED CLINICAL TRIAL", has been accepted for publication in Indian Journal of Orthopaedics.

 Indian Journal of Orthopaedics

Received: 29 November 2023 / Accepted: 30 January 2024
 Indian Orthopaedics Association 2024 

https://link.springer.com/article/10.1007/s43465-024-01117-3

 

#

 

#
22 October , 2023

We have announced our new product Microcore NESC®

Successfully completed Clinical Studies

#
15 November, 2023

Grand Launch of Microcore NESC®

Product Launch in Delhi

#
15 December, 2023

Business associations

Signing Business agreement with the India's leading Pharma Company#####

 

 Contact us

#

 

Address
Registered Office|Unit-1| R&D | QA | Production |
Microcore Research Labs India Pvt Ltd
9th km, 204-A Palani Main Road, Checkumedu,
Erode - 638115 (Dt) Tamil Nadu, India.
info@microcoreresearch.com
www.microcoreresearch.com
www.jointcore.us
www.eggcalcium.com
+91 9659003519